Short Interest in Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY) Rises By 150.0%

Key Points

• Short interest in Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY) rose by 150% in August, increasing from 200 shares to 500 shares.
• The company reported earnings of $0.07 EPS and revenue of $229.16 million in its last quarterly results.
• UBS Group upgraded Ambu A/S to a "strong-buy" rating, confirming its performance amidst a generally positive analyst outlook.

Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY - Get Free Report) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totaling 500 shares, agrowthof150.0% from the July 31st total of 200 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 1.7 days. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 1.7 days.

Analysts Set New Price Targets

Separately, UBS Group upgraded shares of Ambu A/S to a "strong-buy" rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Strong Buy".

Ambu A/S Price Performance

Shares of OTCMKTS:AMBBY remained flat at $14.75 during mid-day trading on Monday. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of 77.63 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.88 and a quick ratio of 1.67. Ambu A/S has a fifty-two week low of $13.02 and a fifty-two week high of $20.24. The firm's 50-day simple moving average is $15.09 and its two-hundred day simple moving average is $16.07.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last released its earnings results on Friday, August 22nd. The company reported $0.07 earnings per share (EPS) for the quarter. The business had revenue of $229.16 million for the quarter. Ambu A/S had a net margin of 5.93% and a return on equity of 6.24%.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.